196 related articles for article (PubMed ID: 37964363)
1. Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.
Omar M; Nuzzo PV; Ravera F; Bleve S; Fanelli GN; Zanettini C; Valencia I; Marchionni L
J Transl Med; 2023 Nov; 21(1):811. PubMed ID: 37964363
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Gene Panel Predictive of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy Employing Transcriptomic and Functional Validation.
Vishnubalaji R; Abdel-Razeq H; Gehani S; Albagha OME; Alajez NM
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142814
[TBL] [Abstract][Full Text] [Related]
3. An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy.
Blaye C; Darbo É; Debled M; Brouste V; Vélasco V; Pinard C; Larmonier N; Pellegrin I; Tarricone A; Arnedos M; Commeny J; Bonnefoi H; Larmonier C; MacGrogan G
ESMO Open; 2022 Aug; 7(4):100502. PubMed ID: 35759853
[TBL] [Abstract][Full Text] [Related]
4. A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
Zheng T; Pang Z; Zhao Z
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30988073
[TBL] [Abstract][Full Text] [Related]
5. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.
Criscitiello C; Bayar MA; Curigliano G; Symmans FW; Desmedt C; Bonnefoi H; Sinn B; Pruneri G; Vicier C; Pierga JY; Denkert C; Loibl S; Sotiriou C; Michiels S; André F
Ann Oncol; 2018 Jan; 29(1):162-169. PubMed ID: 29077781
[TBL] [Abstract][Full Text] [Related]
6. Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.
Zhao Y; Schaafsma E; Cheng C
Cancer Med; 2020 Sep; 9(17):6281-6295. PubMed ID: 32692484
[TBL] [Abstract][Full Text] [Related]
7. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
[TBL] [Abstract][Full Text] [Related]
8. A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors.
Pérez-Pena J; Tibor Fekete J; Páez R; Baliu-Piqué M; García-Saenz JÁ; García-Barberán V; Manzano A; Pérez-Segura P; Esparis-Ogando A; Pandiella A; Gyorffy B; Ocana A
Front Immunol; 2019; 10():2802. PubMed ID: 31921107
[TBL] [Abstract][Full Text] [Related]
9. A Six-Epithelial-Mesenchymal Transition Gene Signature May Predict Metastasis of Triple-Negative Breast Cancer.
Wei LY; Zhang XJ; Wang L; Hu LN; Zhang XD; Li L; Gao JN
Onco Targets Ther; 2020; 13():6497-6509. PubMed ID: 32753890
[TBL] [Abstract][Full Text] [Related]
10. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Marmé F; Solbach C; Michel L; Schneeweiss A; Blohmer JU; Huober J; Fasching PA; Jackisch C; Nekljudova V; Link T; Rhiem K; Rey J; Denkert C; Hanusch C; Tesch H; Lederer B; Loibl S; Untch M
Eur J Cancer; 2021 Aug; 153():203-212. PubMed ID: 34186505
[TBL] [Abstract][Full Text] [Related]
11. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Neoadjuvant
Philipovskiy A; Corral J; Dwivedi KA; Heydarian R; Gaur S
In Vivo; 2019; 33(4):1227-1234. PubMed ID: 31280213
[TBL] [Abstract][Full Text] [Related]
13. qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.
Zuo K; Yuan X; Liang X; Sun X; Liu S; Connell PP; Li X; Yang W
Breast Cancer Res Treat; 2022 Jan; 191(2):335-344. PubMed ID: 34797456
[TBL] [Abstract][Full Text] [Related]
14. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.
Yu KD; Zhu R; Zhan M; Rodriguez AA; Yang W; Wong S; Makris A; Lehmann BD; Chen X; Mayer I; Pietenpol JA; Shao ZM; Symmans WF; Chang JC
Clin Cancer Res; 2013 May; 19(10):2723-33. PubMed ID: 23549873
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer.
Liu YR; Jiang YZ; Xu XE; Hu X; Yu KD; Shao ZM
Clin Cancer Res; 2016 Apr; 22(7):1653-62. PubMed ID: 26813360
[TBL] [Abstract][Full Text] [Related]
16. Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer.
Fisher TB; Saini G; Rekha TS; Krishnamurthy J; Bhattarai S; Callagy G; Webber M; Janssen EAM; Kong J; Aneja R
Breast Cancer Res; 2024 Jan; 26(1):12. PubMed ID: 38238771
[TBL] [Abstract][Full Text] [Related]
17. A Nomogram to Predict Disease-Free Survival Following Neoadjuvant Chemotherapy for Triple Negative Breast Cancer.
Zhu M; Liang C; Zhang F; Zhu L; Chen D
Front Oncol; 2021; 11():690336. PubMed ID: 34745934
[TBL] [Abstract][Full Text] [Related]
18. Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy.
Li J; Chen S; Chen C; Di G; Liu G; Wu J; Shao Z
Oncotarget; 2017 Mar; 8(11):18399-18408. PubMed ID: 27191991
[TBL] [Abstract][Full Text] [Related]
19. Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
Kim EK; Park AK; Ko E; Park WY; Lee KM; Noh DY; Han W
Breast Cancer Res Treat; 2019 Nov; 178(1):185-197. PubMed ID: 31342312
[TBL] [Abstract][Full Text] [Related]
20. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.
Park YH; Jung HH; Do IG; Cho EY; Sohn I; Jung SH; Kil WH; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH
Int J Cancer; 2015 Apr; 136(8):1976-84. PubMed ID: 25537444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
